Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;177(4):559-563.
doi: 10.1007/s10517-024-06223-8. Epub 2024 Sep 12.

Regulatory Effects of 5-Day Oral and Intraperitoneal Administration of a Thienopyrimidine Derivative on the Thyroid Status in Rats

K V Derkach  1 , V N Sorokoumov  2 , I Yu Morina  2 , V S Kuznetsova  2 , I V Romanova  2 , A O Shpakov  2
Affiliations

Regulatory Effects of 5-Day Oral and Intraperitoneal Administration of a Thienopyrimidine Derivative on the Thyroid Status in Rats

K V Derkach et al. Bull Exp Biol Med. 2024 Aug.

Abstract

In experiments on rats, we studied the effect of 5-day intraperitoneal (15 mg/kg/day) and oral (40 mg/kg/day) administration of compound TPY3m, a stimulator of the production of thyroid hormones by the thyroid gland developed by us, on the blood levels of thyroxine, triiodothyronine, and thyroid-stimulating hormone and on morphology of the thyroid gland. With both routes of administration, TPY3m caused a sustained moderate elevation of thyroid hormones, mainly thyroxine, with little effect on the level of thyroid-stimulating hormone. TPY3m did not reduce the stimulating effect of thyroliberin on the levels of thyroid hormones and had no damaging effect on the thyroid gland. During long-term administration, compound TPY3m stimulates the production of thyroid hormones without weakening the activity of the thyroid axis. Thus, TPY3m is a prototype of drugs for correcting thyroid hormone deficiency.

Keywords: allosteric agonist; hypothyroidism; thyroid gland; thyroid-stimulating hormone receptor; thyroxine.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: A review. JAMA. 2019;322(2):153-160. https://doi.org/10.1001/jama.2019.9052 - DOI - PubMed
    1. Bianco AC. Emerging therapies in hypothyroidism. Annu. Rev. Med. 2024;75:307-319. https://doi.org/10.1146/annurev-med-060622-101007 - DOI - PubMed
    1. Saponaro F, Sestito S, Runfola M, Rapposelli S, Chiellini G. Selective thyroid hormone receptor-beta (TRβ) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders. Front. Med. (Lausanne). 2020;7:331. https://doi.org/10.3389/fmed.2020.00331
    1. Marcinkowski P, Kreuchwig A, Mendieta S, Hoyer I, Witte F, Furkert J, Rutz C, Lentz D, Krause G, Schülein R. Thyrotropin receptor: allosteric modulators illuminate intramolecular signaling mechanisms at the interface of ecto- and transmembrane domain. Mol. Pharmacol. 2019;96(4):452-462. https://doi.org/10.1124/mol.119.116947 - DOI - PubMed
    1. Bakhtyukov AA, Derkach KV, Fokina EA, Sorokoumov VN, Zakharova IO, Bayunova LV, Shpakov AO. Development of low-molecular-weight allosteric agonist of thyroid-stimulating hormone receptor with thyroidogenic activity. Dokl. Biochem. Biophys. 2022;503(1):67-70. https://doi.org/10.1134/S1607672922020016 - DOI - PubMed - PMC

LinkOut - more resources